Knowledge base toward understanding actionable alterations and realizing precision oncology

被引：0
作者：
Shiho Takeuchi
Shujiro Okuda
机构：
[1] Niigata University Graduate School of Medical and Dental Sciences,Division of Cancer Genome Informatics
[2] Niigata University Graduate School of Medical and Dental Sciences,Division of Bioinformatics
来源：
International Journal of Clinical Oncology | 2019年 / 24卷
关键词：
Knowledge base; Next-generation sequencing; Precision oncology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In Japan, the National Cancer Center and university hospitals have initiated next-generation sequencing-based in vitro diagnostic testing for cancer patients as a method of clinical sequencing. Based on the molecular alterations detected, physicians can provide approved targeted therapy and access to investigational drugs for cancer patients. However, interpretation of the clinical significance of genomic alterations remains the most severe bottleneck of precision medicine in cancer. Although many research institutes in the United States are developing knowledge bases for interpretation of the tumor alterations and clinical decisions, these knowledge bases are unsuited as sources of reference in Japan due to differences in the information on approved drugs and implementation of clinical trials. In this review, we introduce knowledge bases for clinical decision-making based on genomic events in cancer, and discuss the resources of additional information necessary for implementing precision medicine in Japan.
引用
收藏
页码：123 / 130
页数：7
相关论文
共 110 条
[1]  
Shigematsu H(2005)Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 339-346
[2]  
Lin L(2015)EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII) Am J Cancer Res 5 2892-2911
[3]  
Takahashi T(2007)Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 1817-1824
[4]  
Midha A(2004)EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy Science 302 1497-1500
[5]  
Dearden S(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[6]  
McCormack R(2009)Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 958-967
[7]  
Mitsudomi T(2017)Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Ann Oncol 28 270-277
[8]  
Yatabe Y(2015)Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Lancet Oncol 16 830-838
[9]  
Paez JG(2015)Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial Lancet Oncol 16 897-907
[10]  
Jänne PA(2012)Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial Lancet Oncol 13 539-548
12345678910